Core Viewpoint - ACELYRIN, INC. is urging its stockholders to vote in favor of the proposed merger with Alumis Inc., supported by a recommendation from Institutional Shareholder Services (ISS) [1][2]. Group 1: Proposed Transaction - The special meeting for stockholders to vote on the merger is scheduled for May 13, 2025 [2]. - ISS has recommended that stockholders vote "FOR" the merger, indicating it is the best path to maximize shareholder value [2][3]. - The merger is the result of a comprehensive process led by independent directors, aimed at creating a stronger, diversified company [2]. Group 2: Company Overview - ACELYRIN is a late-stage clinical biopharma company focused on developing transformative medicines in immunology [1][4]. - The company's lead program, lonigutamab, is a monoclonal antibody targeting IGF-1R for treating thyroid eye disease [4]. Group 3: Advisory and Legal Support - Guggenheim Securities, LLC is serving as the financial advisor for ACELYRIN, while Fenwick & West LLP and Paul Hastings LLP are providing legal counsel [3].